Breaking News

Staten Biotechnology and Novo Nordisk in Cardiovascular Tie-up

Collaboration to develop novel treatment for dyslipidaemia; could be worth up to €430 million

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Staten Biotechnology and Novo Nordisk today have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia. Novo Nordisk will provide research and development funding and support for Staten to develop its lead asset STT-5058 for treatment of dyslipidaemia. Under the exclusive option agreement, Novo Nordisk has the right to acquire Staten Biotechnology and gain worldwide rights to STT-5058. Staten Biotechnology and its ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters